In 2002, a pivotal shift occurred within Novo Nordisk when chemists Thomas Kruse and Jesper Lau transitioned their research focus from small molecules to peptide chemistry. This change aimed to develop a long-acting GLP-1 receptor agonist, a class of drugs designed to mimic the natural GLP-1 hormone found in the body.
Initially, Kruse felt this shift was akin to switching trades, as peptide molecules are significantly larger. However, he soon joined forces with Lau and laboratory technician Paw Bloch to embark on creating a groundbreaking GLP-1 receptor agonist. At that time, only two such drugs existed: exenatide and liraglutide, both of which provided a foundation for their research.
After enduring 216 failed attempts, success came in November 2004 when the team modified the GLP-1 molecule by attaching a fatty acid chain. This innovation enhanced the drug's stability by allowing it to bind more effectively to albumin, thus prolonging its half-life in the body. This newly engineered molecule became known as semaglutide, the active ingredient in Ozempic, which gained FDA approval in 2017 for type 2 diabetes treatment, followed by Wegovy for obesity in 2021.
Over two decades later, semaglutide has transformed the landscape of GLP-1 treatments, significantly influencing how diabetes and obesity are managed. In a recent conversation, Kruse and Lau reflected on the challenges they faced during the development process and the unexpected cultural impact of GLP-1 medications on societal views regarding weight and body image.
When asked about the initial GLP-1 drugs, Lau noted that they provided critical insights into the challenges of drug stability and efficacy. Kruse elaborated on the complexities of ensuring that the drug could avoid rapid degradation in the body, emphasizing the importance of balancing molecular size and activity.
The duo celebrated their first positive results in human trials in 2008, marking a significant milestone in their journey. They expressed surprise at the widespread adoption of GLP-1 medications, noting that they had not anticipated the cultural conversations surrounding obesity and body image that would emerge from their work.
As they discussed the future of GLP-1 therapies, both Kruse and Lau acknowledged the potential for semaglutide to contribute to reducing comorbidities associated with obesity, such as cardiovascular diseases. They emphasized that while semaglutide may not eliminate obesity or diabetes entirely, it represents a significant advancement in treatment options.
Looking ahead, the researchers are optimistic about the continued evolution of GLP-1 therapies and their potential to enhance patient outcomes. They believe that ongoing research will uncover even more effective treatments, paving the way for a healthier future for many.